Tempus Announces Strategic Collaboration Agreement with Merck to Accelerate AI-Driven Precision Medicine

“This collaboration builds on our existing relationship and reflects our shared commitment to harnessing the power of multimodal datasets with AI to deliver better options for patients,” said Ryan Fukushima, CEO, Data & Apps at Tempus. “We’ve spent years configuring our Lens Platform to seamlessly leverage our library of de-identified multimodal data with the necessary AI computing power to train and fine-tune specific models for healthcare. Working with the great scientists at Merck, we have exciting opportunities to translate the insights from AI models into precision medicine strategies and improve patient outcomes across oncology and beyond.”

Share:

More News

Taiho Oncology, Inc. completed a New Drug Application (NDA) submission to the U.S. Food and Drug Administration (FDA) for zipalertinib in combination with platinum-based chemotherapy for the treatment of patients with previously untreated, locally advanced or metastatic non-small cell lung cancer (NSCLC) harboring epidermal growth factor receptor (EGFR) exon 20

“This collaboration reflects our conviction that atebimetinib has the potential to become an essential backbone therapy in a broad range of combinations across MAPK-driven cancers,” said Ben Zeskind, Immuneering CEO and co-founder. “Atebimetinib’s unique tolerability profile and broad activity make it well suited to combine with a wide range of

“These final updated results provide continued evidence of the potential for γδ T cell therapies to drive activity and improve outcomes for patients,” said William Ho, CEO and co-founder of IN8bio. “The clinical outcomes and observed activity are supported by our correlative analysis, including histopathology, demonstrating the expansion and persistence

“Patients with RAS-mutated mCRC have no first-line therapies specifically approved for their disease, and Fast Track designation reflects the potential of onvansertib to address this serious unmet need,” said Mani Mohindru, PhD, President and Chief Executive Officer of Cardiff Oncology. “Our randomized Phase 2 data give us confidence that onvansertib